4//SEC Filing
GRANGE DAVID L 4
Accession 0001264908-11-000001
CIK 0001003124other
Filed
Feb 28, 7:00 PM ET
Accepted
Mar 1, 3:43 PM ET
Size
13.1 KB
Accession
0001264908-11-000001
Insider Transaction Report
Form 4
GRANGE DAVID L
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2011-02-28$20.45/sh+34,501$705,545→ 95,546 total - Sale
Common Stock
2011-02-28$26.00/sh−34,501$897,026→ 61,045 total - Exercise/Conversion
Stock Options (to buy)
2011-02-28−34,501→ 69,005 totalExercise: $20.45From: 2011-02-25Exp: 2020-02-25→ Common Stock (34,501 underlying)
Holdings
- 6,485
Stock Options (to buy)
Exercise: $41.32From: 2008-05-21Exp: 2018-05-20→ Common Stock (6,485 underlying) - 155,259
Stock Options (to buy)
Exercise: $21.98From: 2010-07-01Exp: 2019-07-01→ Common Stock (155,259 underlying) - 50,000
Stock Options (to buy)
Exercise: $26.64From: 2011-06-17Exp: 2020-06-17→ Common Stock (50,000 underlying)
Footnotes (4)
- [F1]50,000 shares of restricted stock were granted upon the Reporting Person's acceptance of employment as Chief Executive Officer. These shares vest in four equal increments on 7/1/10, 7/1/11, 7/1/12 and 7/1/13.
- [F2]The options vest in three equal installments on 6/17/11, 6/17/12 and 6/17/13.
- [F3]The options vest in three equal installments on 2/25/11, 2/25/12 and 2/25/13.
- [F4]The options vest in four equal installments of 50,000 on 7/1/10, 7/1/11, 7/1/12 and 7/1/13.
Documents
Issuer
PHARMACEUTICAL PRODUCT DEVELOPMENT INC
CIK 0001003124
Entity typeother
Related Parties
1- filerCIK 0001264908
Filing Metadata
- Form type
- 4
- Filed
- Feb 28, 7:00 PM ET
- Accepted
- Mar 1, 3:43 PM ET
- Size
- 13.1 KB